Clinical Trials Browser

OTHER × Lung Neoplasms × anlotinib × Clear all

NCT07307443 2025-12-29

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

Phase 2 Not yet recruiting

Lung Neoplasms

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT06048315 2023-09-21

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Phase 3 Not yet recruiting

Lung Neoplasms

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Phase 2 Completed

Lung Neoplasms

NCT05319886 2022-05-20

AP

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04731909 2021-02-10

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Phase NA Unknown

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03780283 2018-12-21

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Phase 2 Unknown

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Phase 2 Unknown

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03589950 2018-07-18

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Lung Neoplasms